Letrozole in Uterine Leiomyosarcoma

Patient or a legally authorized representative must have signed an approved informed consent and authorization permitting the release of personal health information.

Patient must have histologically confirmed newly diagnosed uterine leiomyosarcoma with disease limited to the uterus (FIGO 2009 Stage I). Submission of pathology report documenting uterine leiomyosarcoma histology is required in the IRT Source Document Portal following randomization.

Patient tumors must express ER positivity by immunohistochemistry (ER expression greater than 10% by immunohistochemistry). ER status test results must be provided at enrollment. Sites are required to report results of ER status testing in the IRT Source Document Portal.

Patient must have completed hysterectomy and bilateral salpingo-oopherectomy no more than 12 weeks from enrollment.